KCT0006222
尚未招募
未知
Intensity-adjusted SAlvage chemotheraPy Plus FLT3-inHibitor Gilteritinib In RElapsed/refractory acute myeloid leukemia with mutated FLT3-ITD/TKD
概览
- 阶段
- 未知
- 干预措施
- 未指定
- 疾病 / 适应症
- Diseases of the blood and blood-forming organs and certain disorders involving the immune mechanism
- 发起方
- Gachon University Gil Medical Center
- 入组人数
- 26
- 状态
- 尚未招募
- 最后更新
- 4年前
概览
简要总结
暂无简介。
研究者
入排标准
入选标准
- •Relapsed or refractory mutated FLT3\-ITD/TKD AML
- •No prior exposure to Gilteritinib (prior exposure of other FLT3\-inhibitors is permitted including quizartinib or midostaurin)
- •Mean QTcF interval of ECG readings is 480 ms or shorter
- •Written informed consent must be given.
- •Patients must be 19 years of age or older.
排除标准
- •prior exposure to gilteritinib
- •Patients who are not able to receive FLAG\-Ida or LoDAC
- •Acute promyelocytic leukemia with t(15;17\) or PML/RARa rearrangement
- •Patients with CNS involvement of leukemic blasts will not be excluded.
- •Patients with extramedullary relapse(s) only will be excluded.
- •Uncontrolled active infection
- •Uncontrolled bleeding
- •Patients who are pregnant or lactating.
- •Patients having a psychiatric disorder or mental deficiency severe as to make compliance with the treatment unlike, and making informed consent impossible.
结局指标
主要结局
未指定
相似试验
进行中（未招募）
2 期
Optimising therapy in FLT3-mutated acute myeloid leukaemiaAcute myeloid leukemiaCancerISRCTN34016918Cardiff University390
招募中
1 期
A phase 3b, interventional, adaptive, clinical trial to evaluate the efficacy and safety of tralokinumab 300 mg every second week monotherapy compared with placebo in subjects with moderate-to-severe atopic hand eczema who are candidates for systemic therapy (ADHAND)Atopic dermatitis and moderate-to severe atopic hand eczemaMedDRA version: 21.1Level: LLTClassification code: 10003639Term: Atopic dermatitis Class: 10040785MedDRA version: 21.1Level: LLTClassification code: 10003641Term: Atopic eczema Class: 10040785Therapeutic area: Diseases [C] - Skin and Connective Tissue Diseases [C17]CTIS2022-502653-34-01EO PHARMA A/S402
招募中
4 期
ADO CTCL-3 (Tarado): Multicentric therapy protocol for bexarotene (Targretin ®) monotherapy in pretreated CTCL stage =Ib with clear assignment to a EORTC-DiagnosisTCELLLYMPHOMAC84Mature T/NK-cell lymphomasDRKS00003693niversitätsklinikum Schleswig-Holstein Campus Kiel200
进行中（未招募）
1 期
Randomized Phase III Study of Intensive Chemotherapy with or without Dasatinib (Sprycel™) in Adult Patients with Newly Diagnosed Core-Binding Factor Acute Myeloid Leukemia (CBF-AML)ewly Diagnosed Core-Binding FactorAcute Myeloid Leukemia (CBF-AML)Therapeutic area: Diseases [C] - Blood and lymphatic diseases [C15]EUCTR2013-003117-18-ATniversitätsklinikum Ulm203
进行中（未招募）
1 期
Randomized Phase III Study of Intensive Chemotherapy with or without Dasatinib (Sprycel™) in Adult Patients with Newly Diagnosed Core-Binding Factor Acute Myeloid Leukemia (CBF-AML)ewly Diagnosed Core-Binding FactorAcute Myeloid Leukemia (CBF-AML)Therapeutic area: Diseases [C] - Blood and lymphatic diseases [C15]EUCTR2013-003117-18-DEniversity Hospital Ulm203